Clinical trials: Head and Neck Squamous Cell Carcinomas
Esophageal Cancer
Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
RATIONALE: Drugs used in chemotherapy such as paclitaxel, fluorouracil, and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00069953
- Testing
- filgrastim, pegfilgrastim, cisplatin
- Where
- 97 sites in United States
- Volunteers
- 43 people
- Sponsor
- Radiation Therapy Oncology Group
Locally Advanced Head and Neck Squamous Cell Carcinoma
Sintilimab Plus Hypofractionated Radiotherapy Followed by Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
Most patients with head and neck squamous cell carcinoma (HNSCC) are diagnosed with locally advanced disease. While cisplatin-based chemoradiotherapy remains the standard-of-care treatment for this patient population, it is still…
- Trial name
- NCT07781072
- Testing
- Hypofractionated Induction RT (5Gy×3) Followed by Sintilimab, Platinum-Based CCRT and Sintilimab
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Esophageal Squamous Cell Carcinoma
A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer
The purpose of this study is to test the the efficacy and safety of sintilimab in combination with chemoradiation before surgery for esophageal cancer.
- Trial name
- NCT03940001
- Testing
- Sintilimab, carboplatin/paclitaxel, Radiation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Head and Neck Squamous Cell Carcinoma
Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC
A phase Ⅱ open label multi-cencter clinical trail to evaluate the efficacy and safety of pembrolizumab combined with low-dose PF (cisplatin + 5-fluorouracil) in the neoadjuvant treatment of locally advanced head and neck squamous…
- Trial name
- NCT05446467
- Testing
- pembrolizumab+cisplatin + 5-FU
- Where
- 7 sites in China
- Volunteers
- 80 people
- Sponsor
- Zhejiang Provincial People's Hospital
Esophageal Squamous Cell Carcinoma
Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer Patients
The purpose of this study is to evaluate the efficacy and safety of neoadjuvant chemotherapy with nab-paclitaxel plus cisplatin for stage Ⅱ-Ⅲ esophageal squamous cell carcinoma patients.
- Trial name
- nabPCESCC (NCT01258192)
- Testing
- albumin-bound paclitaxel plus cisplatin
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhejiang Cancer Hospital
Oropharyngeal Squamous Cell Carcinoma
Ex Vivo 3D-ultrasound for Oropharyngeal Cancer
Patients with biopsy-verified oropharyngeal squamous cell carcinomas treated with transoral robotic surgery are included. Immediately post-operatively, freshly resected specimens are examined with ex vivo 3D ultrasound (US).
- Trial name
- NCT06314711
- Testing
- Ultrasound
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Head and Neck Cancer
Metronomic Chemotherapy With Tegafur/Uracil for Head and Neck Squamous Cell Carcinoma
It is the investigators understanding that the combination of clinical trial with laboratory cellular/molecular assay is relevant to the current promising mainstream, the translational research.
- Trial name
- NCT00855881
- Testing
- tegafur-uracil
- Where
- Taiwan
- Volunteers
- 115 people
- Sponsor
- Mackay Memorial Hospital
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
This phase II trial studies how well dasatinib works in treating patients with head and neck cancer that has come back or spread to other areas of the body.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00507767
- Testing
- dasatinib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
HPV, Oropharyngeal Squamous Cell Carcinoma
Post-treatment Surveillance in HPV+ Oropharyngeal SCC
In this research study the investigators are examining a blood test to detect HPV DNA in the blood that can possibly detect cancer recurrence earlier than with standard surveillance measures.
- Trial name
- NCT04965792
- Testing
- Screening
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Dana-Farber Cancer Institute
Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma
Stereotactic Body Radiotherapy for Head and Neck Tumors
This study will evaluate the local control rates as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of benign and malignant head and neck tumors.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Salivary Gland Cancer, Head and Neck Sarcoma
- Trial name
- NCT01344356
- Testing
- stereotactic body radiotherapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mercy Research
Laryngeal Cancer Stage II, Laryngeal Cancer Stage III
Olaparib and Radiotherapy in Head and Neck Cancer
Accelerated, normofractionated radiotherapy is the treatment of choice in stage II-III laryngeal and oropharyngeal squamous cell carcinoma (SCC).
- Conditions
- Laryngeal Cancer Stage II, Laryngeal Cancer Stage III, Carcinoma, Squamous Cell, Head and Neck Neoplasms
- Trial name
- NCT02229656
- Testing
- radiotherapy, Olaparib
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- The Netherlands Cancer Institute
Cancer of Head and Neck, Squamous Cell Carcinoma of the Head and Neck
Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck
The purpose of this study is to determine the safety and tumor debulking efficacy of personalized anti-cancer vaccine AlloVax(TM) in Subjects with confirmed recurrent or metastatic squamous cell carcinoma of the head and neck…
- Trial name
- HNC (NCT01998542)
- Testing
- AlloVax, CRCL, AlloStim
- Where
- Thailand
- Volunteers
- 12 people
- Sponsor
- Mirror Biologics, Inc.
Hearing Loss, Head and Neck Cancer
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
Background: Cisplatin is used to treat head and neck cancer. People who take this drug are at risk for hearing loss. Atorvastatin is a drug used to treat high cholesterol.
- Trial name
- NCT04915183
- Testing
- Atorvastatin
- Where
- 5 sites in United States
- Volunteers
- 224 people
- Sponsor
- National Institute on Deafness and Other Communication Disorders (NIDCD)
Melanoma, Breast Cancer
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
The Serpentine (Stratify cancER PatiENTs by ImmuNosupprEssion) project, represents the most consistent effort so far attempted to translate MDSC into clinical practise by producing an off-the-shelf compliant assay for quantifying…
- Conditions
- Melanoma, Breast Cancer, Renal Cell Carcinoma, Urinary Bladder Cancer
- Trial name
- Serpentine (NCT05621837)
- Testing
- MDSC quantification
- Where
- Italy
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Head and Neck Cancer
Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00646659
- Testing
- cetuximab, carboplatin, cisplatin
- Where
- Belgium
- Volunteers
- 47 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Head and Neck Squamous Cell Carcinoma
A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis
To investigate what the body does to single doses of Sativex (i.e. the pharmacokinetics [PKs] of four sprays containing 10.8 mg Δ9 tetrahydrocannabinol [THC] and 10 mg cannabidiol [CBD]) when mild, moderate or severe oral…
- Trial name
- NCT01975688
- Testing
- Sativex
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- GW Pharmaceuticals Ltd
Head and Neck Squamous Cell Cancer
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
This is a study of pembrolizumab (MK-3475, KEYTRUDA®) versus standard treatment (methotrexate, docetaxel or cetuximab) for the treatment of recurrent or metastatic head and neck squamous cell cancer (HNSCC).
- Trial name
- NCT02252042
- Testing
- Pembrolizumab, Methotrexate, Docetaxel
- Volunteers
- 495 people
- Sponsor
- Merck Sharp & Dohme LLC
Squamous Cell Carcinoma of Head and Neck
Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC
This is a prospective, single center phase II clinical study with a planned enrollment of 33 patients. The main objective is to evaluate the efficacy and safety of the PD-1 inhibitor toripalimab combined with cetuximab…
- Trial name
- NCT06081582
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 33 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer
Amifostine to Treat Side Effects of Treatment in Patients Receiving Radiation Therapy and Cisplatin for Advanced Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00003580
- Testing
- amifostine trihydrate, cisplatin, radiation therapy
- Where
- United States
- Sponsor
- University of Tennessee
Esophageal Squamous Cell Carcinoma
Impact of Preserving Versus Ligating the Right Gastric Artery on Anastomotic Outcomes After McKeown Esophagectomy: A Randomized Controlled Trial
This randomized controlled trial evaluates the impact of preserving versus ligating the Right Gastric Artery (RGA) on postoperative anastomotic complications in patients undergoing McKeown minimally invasive esophagectomy (MIE)…
- Trial name
- NCT07363629
- Testing
- McKeown MIE with RGA Preservation, McKeown MIE with RGA Ligation
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The First Hospital of Hebei Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.